---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-25-000025"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:50:58.200245+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q1 revenue falls 4% to $585M; full-year 2025 outlook moderated on uncertainty

## Summary
- Revenue $585.4M, down from $610.8M YoY; GAAP gross margin 52.3% vs 53.4%.
- GAAP net income $64.0M ($2.29 EPS) vs $383.9M ($13.45 EPS) in Q1 2024.
- Non-GAAP net income $71.0M ($2.54 EPS) vs $65.3M ($2.30 EPS) YoY.
- CEO cites market uncertainty; moderating full-year 2025 outlook.
- Non-GAAP gross margin 53.8%, slightly down from 54.2% a year ago.

## SEC filing metadata
- accession: 0000012208-25-000025
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220825000025/0000012208-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220825000025/bio-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-25-000025
- JSON: https://secwatch.observer/filing/0000012208-25-000025.json
- Plain text: https://secwatch.observer/filing/0000012208-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.